Search Results - "Vaz, Victor R"

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status by Ricciuti, Biagio, Arbour, Kathryn C, Lin, Jessica J, Vajdi, Amir, Vokes, Natalie, Hong, Lingzhi, Zhang, Jianjun, Tolstorukov, Michael Y, Li, Yvonne Y, Spurr, Liam F, Cherniack, Andrew D, Recondo, Gonzalo, Lamberti, Giuseppe, Wang, Xinan, Venkatraman, Deepti, Alessi, Joao V, Vaz, Victor R, Rizvi, Hira, Egger, Jacklynn, Plodkowski, Andrew J, Khosrowjerdi, Sara, Digumarthy, Subba, Park, Hyesun, Vaz, Nuno, Nishino, Mizuki, Sholl, Lynette M, Barbie, David, Altan, Mehmet, Heymach, John V, Skoulidis, Ferdinandos, Gainor, Justin F, Hellmann, Matthew D, Awad, Mark M

“…STK11 and KEAP1 mutations (STK11 mutant [STK11 ] and KEAP1 ) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 has been…”
Get more information

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer by Alessi, Joao V, Ricciuti, Biagio, Alden, Stephanie L, Bertram, Arrien A, Lin, Jessica J, Sakhi, Mustafa, Nishino, Mizuki, Vaz, Victor R, Lindsay, James, Turner, Madison M, Pfaff, Kathleen, Sharma, Bijaya, Felt, Kristen D, Rodig, Scott J., Gainor, Justin F., Awad, Mark M.

“…BackgroundAn elevated peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is a negative prognostic marker for patients with non-small cell lung…”
Get full text

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels by Ricciuti, Biagio, Wang, Xinan, Alessi, Joao V, Rizvi, Hira, Mahadevan, Navin R, Li, Yvonne Y, Polio, Andrew, Lindsay, James, Umeton, Renato, Sinha, Rileen, Vokes, Natalie I, Recondo, Gonzalo, Lamberti, Giuseppe, Lawrence, Marissa, Vaz, Victor R, Leonardi, Giulia C, Plodkowski, Andrew J, Gupta, Hersh, Cherniack, Andrew D, Tolstorukov, Michael Y, Sharma, Bijaya, Felt, Kristen D, Gainor, Justin F, Ravi, Arvind, Getz, Gad, Schalper, Kurt A, Henick, Brian, Forde, Patrick, Anagnostou, Valsamo, Jänne, Pasi A, Van Allen, Eliezer M, Nishino, Mizuki, Sholl, Lynette M, Christiani, David C, Lin, Xihong, Rodig, Scott J, Hellmann, Matthew D, Awad, Mark M

“…Although tumor mutation burden (TMB) has been explored as a potential biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus…”
Get more information

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC by Alessi, Joao V, Elkrief, Arielle, Ricciuti, Biagio, Wang, Xinan, Cortellini, Alessio, Vaz, Victor R, Lamberti, Giuseppe, Frias, Rosa L, Venkatraman, Deepti, Fulgenzi, Claudia A M, Pecci, Federica, Recondo, Gonzalo, Di Federico, Alessandro, Barrichello, Adriana, Park, Hyesun, Nishino, Mizuki, Hambelton, Grace M, Egger, Jacklynn V, Ladanyi, Marc, Digumarthy, Subba, Johnson, Bruce E, Christiani, David C, Lin, Xihong, Gainor, Justin F, Lin, Jessica J, Pinato, David J, Schoenfeld, Adam J, Awad, Mark M

“…Although programmed cell death protein 1 and programmed death-ligand 1 (PD-L1) blockade in combination with platinum-doublet chemotherapy has become a mainstay…”
Get more information

Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer by Ricciuti, Biagio, Lamberti, Giuseppe, Puchala, Sreekar R, Mahadevan, Navin R, Lin, Jia-Ren, Alessi, Joao V, Chowdhury, Alexander, Li, Yvonne Y, Wang, Xinan, Spurr, Liam, Pecci, Federica, Di Federico, Alessandro, Venkatraman, Deepti, Barrichello, Adriana P, Gandhi, Malini, Vaz, Victor R, Pangilinan, Andy J, Haradon, Danielle, Lee, Elinton, Gupta, Hersh, Pfaff, Kathleen L, Welsh, Emma L, Nishino, Mizuki, Cherniack, Andrew D, Johnson, Bruce E, Weirather, Jason L, Dryg, Ian D, Rodig, Scott J, Sholl, Lynette M, Sorger, Peter, Santagata, Sandro, Umeton, Renato, Awad, Mark M

“…Although immune checkpoint inhibitors (ICI) have extended survival in patients with non-small-cell lung cancer (NSCLC), acquired resistance (AR) to ICI…”
Get full text

Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival by Nishino, Mizuki, Wang, Xinan, Ricciuti, Biagio, Tseng, Shu-Chi, Park, Hyesun, Alessi, Joao V., Vaz, Victor R., Hatabu, Hiroto, Lin, Xihong, Christiani, David C., Awad, Mark M.

“…Objectives The study investigated tumor burden dynamics on computed tomography (CT) scans in patients with advanced non-small-cell lung cancer (NSCLC) during…”
Get full text

Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer by Ricciuti, Biagio, Elkrief, Arielle, Alessi, Joao, Wang, Xinan, Li, Yvonne, Gupta, Hersh, Muldoon, Daniel M, Bertram, Arrien A, Pecci, Federica, Lamberti, Giuseppe, Di Federico, Alessandro, Barrichello, Adriana, Vaz, Victor R, Gandhi, Malini, Lee, Elinton, Shapiro, Geoffrey I, Park, Hyesun, Nishino, Mizuki, Lindsay, James, Felt, Kristen D, Sharma, Bijaya, Cherniack, Andrew D, Rodig, Scott, Gomez, Daniel R, Shaverdian, Narek, Rakaee, Mehrdad, Bandlamudi, Chaitanya, Ladanyi, Marc, Janne, Pasi A, Schoenfeld, Adam J, Sholl, Lynette M, Awad, Mark M, Cheng, Michael L

“…ATM is the most commonly mutated DNA damage and repair gene in non-small cell lung cancer (NSCLC); however, limited characterization has been pursued…”
Get full text

Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC by Alessi, Joao V, Wang, Xinan, Elkrief, Arielle, Ricciuti, Biagio, Li, Yvonne Y, Gupta, Hersh, Spurr, Liam F, Rizvi, Hira, Luo, Jia, Pecci, Federica, Lamberti, Giuseppe, Recondo, Gonzalo, Venkatraman, Deepti, Di Federico, Alessandro, Gandhi, Malini M, Vaz, Victor R, Nishino, Mizuki, Sholl, Lynette M, Cherniack, Andrew D, Ladanyi, Marc, Price, Adam, Richards, Allison L, Donoghue, Mark, Lindsay, James, Sharma, Bijaya, Turner, Madison M, Pfaff, Kathleen L, Felt, Kristen D, Rodig, Scott J, Lin, Xihong, Meyerson, Matthew L, Johnson, Bruce E, Christiani, David C, Schoenfeld, Adam J, Awad, Mark M

“…Although gene-level copy number alterations have been studied as a potential biomarker of immunotherapy efficacy in NSCLC, the impact of aneuploidy burden and…”
Get more information

Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors by Pecci, Federica, Nakazawa, Seshiru, Ricciuti, Biagio, Harada, Guilherme, Lee, Jessica K, Alessi, Joao V, Barrichello, Adriana, Vaz, Victor R, Lamberti, Giuseppe, Di Federico, Alessandro, Gandhi, Malini M, Gazgalis, Dimitris, Feng, William W, Jiang, Jie, Baldacci, Simon, Locquet, Marie-Anaïs, Gottlieb, Felix H, Chen, Monica F, Lee, Elinton, Haradon, Danielle, Smokovich, Anna, Voligny, Emma, Nguyen, Tom, Goel, Vikas K, Zimmerman, Zachary, Atwal, Sumandeep, Wang, Xinan, Bahcall, Magda, Heist, Rebecca S, Iqbal, Sumaiya, Gandhi, Nishant, Elliott, Andrew, Vanderwalde, Ari M, Ma, Patrick C, Halmos, Balazs, Liu, Stephen V, Che, Jianwei, Schrock, Alexa B, Drilon, Alexander, Jänne, Pasi A, Awad, Mark M

“…Activating point mutations in the MET tyrosine kinase domain (TKD) are oncogenic in a subset of papillary renal cell carcinomas. Here, using comprehensive…”
Get more information

Response to Crizotinib After Entrectinib Resistance in ROS1 -Rearranged, MET -Amplified Lung Adenocarcinoma by Vaz, Victor R, Gandhi, Malini M, Ricciuti, Biagio, Alessi, Joao V, Elkrief, Arielle, Ladanyi, Marc, Vanderbilt, Chad, Pecci, Federica, Aldea, Mihaela, Barrichello, Adriana, Saini, Arushi, Sholl, Lynette, Sands, Jacob M, Awad, Mark M

“…Crizotinib successfully overcomes MET amplification in ROS1-rearranged NSCLC after entrectinib failure…”
Get more information

Impact of STK11 copy loss on clinical outcomes to PD-(L)1 blockade in non–small cell lung cancer by Gutierrez, Catherine, Ricciuti, Biagio, Alessi, Joao Victor Machado, Pecci, Federica, Barrichello, Adriana Paula de Castro, Vaz, Victor R., Sholl, Lynette M., Awad, Mark M.

“…9059 Background: STK11 is among the most commonly altered genes in non-squamous lung cancers. While STK11 mutation is associated with diminished efficacy of…”
Get full text

Distinct genomic and immunophenotypic features of solid-predominant versus nonsolid-predominant stage I lung adenocarcinomas and association with disease recurrence after surgical resection by Alessi, Joao Victor Machado, Wei, Zihan, Ricciuti, Biagio, Vaz, Victor R., Barrichello, Adriana Paula de Castro, Lamberti, Giuseppe, Sharma, Bijaya, Pfaff, Kathleen L., Felt, Kristen, Turner, Madison M., Rodig, Scott J., Sholl, Lynette M., Awad, Mark M.

“…8514 Background: Compared to lung adenocarcinomas (LUAD) with nonsolid-predominant histology (lepidic, acinar, papillary, micropapillary), those with…”
Get full text

Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC) by Ricciuti, Biagio, Alessi, Joao Victor Machado, Li, Yvonne Y., Vaz, Victor R., Pecci, Federica, Lamberti, Giuseppe, Barrichello, Adriana Paula de Castro, Gupta, Hersh, Nishino, Mizuki, Cherniack, Andrew D., Sholl, Lynette M., Rodig, Scott J., Awad, Mark M.

“…9021 Background: Despite improvements in survival with immune checkpoint inhibition (ICI), the majority of patients develop acquired resistance to ICI after an…”
Get full text

Immunophenotypic correlates and response to first-line pembrolizumab among elderly patients with PD-L1-high (≥ 50%) non–small cell lung cancer by Barrichello, Adriana Paula de Castro, Alessi, Joao Victor Machado, Ricciuti, Biagio, Pecci, Federica, Vaz, Victor R., Lamberti, Giuseppe, Turner, Madison M., Pfaff, Kathleen L., Rodig, Scott J., Awad, Mark M.

“…9054 Background: Older age is associated with increased levels of systemic inflammation and altered immunosurveillance in cancer. Whether aging correlates with…”
Get full text

Activating MET kinase domain mutations define a novel molecular subtype of non–small cell lung cancer that is clinically targetable with the MET inhibitor elzovantinib (TPX-0022) by Pecci, Federica, Ricciuti, Biagio, Alessi, Joao Victor Machado, Barrichello, Adriana Paula de Castro, Vaz, Victor R., Lamberti, Giuseppe, Lee, Jessica Kim, Schrock, Alexa Betzig, Goel, Vikas K, Zimmerman, Zach, Bahcall, Magda, Janne, Pasi A., Awad, Mark M.

“…9124 Background: In non-small cell lung cancer (NSCLC), MET exon 14 skipping (METex14) mutations and MET amplification can be targeted with MET inhibitors…”
Get full text

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations by Cortellini, Alessio, Ricciuti, Biagio, Vaz, Victor R, Soldato, Davide, Alessi, Joao V, Dall’Olio, Filippo G, Banna, Giuseppe L, Muthuramalingam, Sethupathi, Chan, Samuel, Majem, Margarita, Piedra, Aida, Lamberti, Giuseppe, Andrini, Elisa, Addeo, Alfredo, Friedlaender, Alex, Facchinetti, Francesco, Gorría, Teresa, Mezquita, Laura, Hoton, Delphine, Valerie, Lacroix, Nana, Frank Aboubakar, Artingstall, James, Comins, Charles, Di Maio, Massimo, Caglio, Andrea, Cave, Judith, McKenzie, Hayley, Newsom-Davis, Thomas, Evans, Joanne S, Tiseo, Marcello, D'Alessio, Antonio, Fulgenzi, Claudia A M, Besse, Benjamin, Awad, Mark M, Pinato, David J

“…IntroductionIt has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in…”
Get full text

Abstract 2143: Clinicopathologic, genomic and immunophenotypic landscape of ATM mutations in non-small cell lung cancer by Ricciuti, Biagio, Alessi, Joao Victor, Wang, Xinan, Bertram, Arrien A., Vaz, Victor R., Nishino, Mizuki, Lindsay, James, Felt, Kristen D., Sharma, Bijaya, Sholl, Lynette M., Scott, Rodig, Awad, Mark M., Cheng, Michael L.

“…Abstract Introduction: Defective DNA damage repair machinery is a hallmark of cancer, resulting in increased mutation rates and genomic instability. In…”
Get full text

Abstract 506: Dissecting the genomic and tumor immune microenvironment factors associated with disease recurrence in resected stage I NSCLC by Alessi, Joao Victor, Wei, Zihan, Ricciuti, Biagio, Lindsay, James, Vaz, Victor R., Barrichello, Adriana, Sharma, Bijaya, Felt, Kristen D., Hong, Fangxin, Sholl, Lynette M., Rodig, Scott J., Awad, Mark M.

“…Abstract Background: Patients with early-stage non-small cell lung cancer (NSCLC) are at substantial risk for disease recurrence after surgical resection, and…”
Get full text